PortfoliosLab logo
AbCellera Biologics Inc. (ABCL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

CA00288U1066

CUSIP

00288U106

IPO Date

Dec 11, 2020

Highlights

Market Cap

$605.80M

EPS (TTM)

-$0.55

Total Revenue (TTM)

$18.88M

Gross Profit (TTM)

-$71.35M

EBITDA (TTM)

-$164.12M

Year Range

$1.89 - $4.34

Target Price

$11.43

Short %

10.35%

Short Ratio

5.88

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

AbCellera Biologics Inc. (ABCL) returned -30.72% year-to-date (YTD) and -47.00% over the past 12 months.


ABCL

YTD

-30.72%

1M

-1.93%

6M

-24.81%

1Y

-47.00%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of ABCL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20258.19%-18.45%-13.73%17.04%-22.22%-30.72%
2024-10.51%-1.17%-10.30%-16.56%3.70%-24.49%10.14%-21.47%1.56%5.00%10.26%-2.66%-48.69%
20233.95%-20.23%-10.24%-10.08%2.80%-7.32%19.66%-29.50%-15.60%-10.65%14.60%21.23%-43.63%
2022-37.13%-3.11%11.94%-21.33%-0.65%39.76%-5.73%6.37%-7.40%19.62%8.79%-21.29%-29.16%
202131.29%-28.62%-9.94%-21.53%0.68%-18.00%-31.05%10.61%19.43%-21.61%-4.77%-4.41%-64.46%
2020-31.68%-31.68%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ABCL is 13, meaning it’s performing worse than 87% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ABCL is 1313
Overall Rank
The Sharpe Ratio Rank of ABCL is 1212
Sharpe Ratio Rank
The Sortino Ratio Rank of ABCL is 1212
Sortino Ratio Rank
The Omega Ratio Rank of ABCL is 1515
Omega Ratio Rank
The Calmar Ratio Rank of ABCL is 1919
Calmar Ratio Rank
The Martin Ratio Rank of ABCL is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AbCellera Biologics Inc. (ABCL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

AbCellera Biologics Inc. Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: -0.75
  • All Time: -0.79

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of AbCellera Biologics Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


AbCellera Biologics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the AbCellera Biologics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AbCellera Biologics Inc. was 96.72%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current AbCellera Biologics Inc. drawdown is 96.55%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.72%Dec 14, 20201084Apr 8, 2025

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AbCellera Biologics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of AbCellera Biologics Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 11.8% positive surprise.


-0.200.000.200.400.6020212022202320242025
-0.15
-0.17
Actual
Estimate

Valuation

The Valuation section provides an overview of how AbCellera Biologics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ABCL relative to other companies in the Biotechnology industry. Currently, ABCL has a P/S ratio of 21.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ABCL in comparison with other companies in the Biotechnology industry. Currently, ABCL has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items